vs
CareDx, Inc.（CDNA）与REPUBLIC BANCORP INC（RBCAA）财务数据对比。点击上方公司名可切换其他公司
CareDx, Inc.的季度营收约是REPUBLIC BANCORP INC的1.2倍（$117.7M vs $94.3M），REPUBLIC BANCORP INC净利率更高（24.2% vs 2.4%，领先21.8%），CareDx, Inc.同比增速更快（39.0% vs 5.3%），REPUBLIC BANCORP INC自由现金流更多（$161.1M vs $514.0K），过去两年CareDx, Inc.的营收复合增速更高（12.9% vs -11.5%）
CareDx是一家专注于器官移植领域的精准医疗企业，核心产品包括移植排斥反应监测诊断试剂、数字健康管理工具及配套临床服务，面向北美和欧洲市场的医疗机构及移植患者，助力提升术后患者生存质量。
肯塔基州共和银行是美国的一家区域性银行控股企业，提供零售及商业银行全品类服务，涵盖个人存贷款、企业融资、按揭产品及财富管理解决方案，主要服务肯塔基州及周边州的个人消费者和中小企业客户。
CDNA vs RBCAA — 直观对比
营收规模更大
CDNA
是对方的1.2倍
$94.3M
营收增速更快
CDNA
高出33.7%
5.3%
净利率更高
RBCAA
高出21.8%
2.4%
自由现金流更多
RBCAA
多$160.6M
$514.0K
两年增速更快
CDNA
近两年复合增速
-11.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $117.7M | $94.3M |
| 净利润 | $2.8M | $22.8M |
| 毛利率 | — | — |
| 营业利润率 | — | 29.3% |
| 净利率 | 2.4% | 24.2% |
| 营收同比 | 39.0% | 5.3% |
| 净利润同比 | — | 20.0% |
| 每股收益（稀释后） | $0.05 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CDNARBCAA
| Q1 26 | $117.7M | — | ||
| Q4 25 | $108.4M | $94.3M | ||
| Q3 25 | $100.1M | $93.5M | ||
| Q2 25 | $86.7M | $93.8M | ||
| Q1 25 | $84.7M | $135.8M | ||
| Q4 24 | $86.6M | $89.5M | ||
| Q3 24 | $82.9M | $88.1M | ||
| Q2 24 | $92.3M | $86.9M |
净利润CDNARBCAA
| Q1 26 | $2.8M | — | ||
| Q4 25 | $-4.1M | $22.8M | ||
| Q3 25 | $1.7M | $29.7M | ||
| Q2 25 | $-8.6M | $31.5M | ||
| Q1 25 | $-10.4M | $47.3M | ||
| Q4 24 | $87.7M | $19.0M | ||
| Q3 24 | $-10.6M | $26.5M | ||
| Q2 24 | $-4.6M | $25.2M |
营业利润率CDNARBCAA
| Q1 26 | — | — | ||
| Q4 25 | -5.6% | 29.3% | ||
| Q3 25 | -0.2% | 40.4% | ||
| Q2 25 | -12.8% | 43.0% | ||
| Q1 25 | -15.8% | 44.1% | ||
| Q4 24 | 97.5% | 25.8% | ||
| Q3 24 | -16.6% | 38.4% | ||
| Q2 24 | -7.9% | 37.0% |
净利率CDNARBCAA
| Q1 26 | 2.4% | — | ||
| Q4 25 | -3.8% | 24.2% | ||
| Q3 25 | 1.7% | 31.8% | ||
| Q2 25 | -9.9% | 33.5% | ||
| Q1 25 | -12.2% | 34.8% | ||
| Q4 24 | 101.3% | 21.2% | ||
| Q3 24 | -12.8% | 30.1% | ||
| Q2 24 | -5.0% | 29.0% |
每股收益（稀释后）CDNARBCAA
| Q1 26 | $0.05 | — | ||
| Q4 25 | $-0.08 | — | ||
| Q3 25 | $0.03 | — | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $1.60 | — | ||
| Q3 24 | $-0.20 | — | ||
| Q2 24 | $-0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $77.9M | $220.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $1.1B |
| 总资产 | $411.1M | $7.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CDNARBCAA
| Q1 26 | $77.9M | — | ||
| Q4 25 | $177.2M | $220.0M | ||
| Q3 25 | $194.2M | $484.2M | ||
| Q2 25 | $186.3M | $484.8M | ||
| Q1 25 | $230.9M | $793.0M | ||
| Q4 24 | $260.7M | $432.2M | ||
| Q3 24 | $240.9M | $530.9M | ||
| Q2 24 | $228.9M | $400.1M |
总债务CDNARBCAA
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — |
股东权益CDNARBCAA
| Q1 26 | — | — | ||
| Q4 25 | $303.1M | $1.1B | ||
| Q3 25 | $311.1M | $1.1B | ||
| Q2 25 | $327.4M | $1.1B | ||
| Q1 25 | $379.3M | $1.0B | ||
| Q4 24 | $378.4M | $992.0M | ||
| Q3 24 | $273.2M | $979.7M | ||
| Q2 24 | $264.7M | $955.4M |
总资产CDNARBCAA
| Q1 26 | $411.1M | — | ||
| Q4 25 | $413.2M | $7.0B | ||
| Q3 25 | $432.3M | $7.0B | ||
| Q2 25 | $444.3M | $7.0B | ||
| Q1 25 | $489.6M | $7.1B | ||
| Q4 24 | $491.1M | $6.8B | ||
| Q3 24 | $477.0M | $6.7B | ||
| Q2 24 | $466.8M | $6.6B |
负债/权益比CDNARBCAA
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.3M | $168.2M |
| 自由现金流经营现金流 - 资本支出 | $514.0K | $161.1M |
| 自由现金流率自由现金流/营收 | 0.4% | 170.9% |
| 资本支出强度资本支出/营收 | — | 7.5% |
| 现金转化率经营现金流/净利润 | 1.54× | 7.37× |
| 过去12个月自由现金流最近4个季度 | — | $288.6M |
8季度趋势，按日历期对齐
经营现金流CDNARBCAA
| Q1 26 | $4.3M | — | ||
| Q4 25 | $21.4M | $168.2M | ||
| Q3 25 | $37.4M | $33.3M | ||
| Q2 25 | $9.9M | $8.4M | ||
| Q1 25 | $-26.6M | $93.2M | ||
| Q4 24 | $21.9M | $149.0M | ||
| Q3 24 | $12.5M | $51.3M | ||
| Q2 24 | $18.9M | $4.0M |
自由现金流CDNARBCAA
| Q1 26 | $514.0K | — | ||
| Q4 25 | — | $161.1M | ||
| Q3 25 | — | $30.8M | ||
| Q2 25 | — | $5.2M | ||
| Q1 25 | — | $91.6M | ||
| Q4 24 | — | $143.2M | ||
| Q3 24 | — | $49.8M | ||
| Q2 24 | — | $2.7M |
自由现金流率CDNARBCAA
| Q1 26 | 0.4% | — | ||
| Q4 25 | — | 170.9% | ||
| Q3 25 | — | 32.9% | ||
| Q2 25 | — | 5.5% | ||
| Q1 25 | — | 67.4% | ||
| Q4 24 | — | 160.0% | ||
| Q3 24 | — | 56.5% | ||
| Q2 24 | — | 3.1% |
资本支出强度CDNARBCAA
| Q1 26 | — | — | ||
| Q4 25 | — | 7.5% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 6.5% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 1.5% |
现金转化率CDNARBCAA
| Q1 26 | 1.54× | — | ||
| Q4 25 | — | 7.37× | ||
| Q3 25 | 22.30× | 1.12× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 1.97× | ||
| Q4 24 | 0.25× | 7.84× | ||
| Q3 24 | — | 1.93× | ||
| Q2 24 | — | 0.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CDNA
| Testing services revenue | $91.4M | 78% |
| Patient and digital solutions revenue | $16.0M | 14% |
| Product revenue | $10.3M | 9% |
RBCAA
暂无分部数据
